Skip to main content
evidena care

Law

Cannabis pilot trials in Switzerland: overview and difference

Authorised studies on recreational cannabis use are running in several Swiss cities. What they research and why they are not a route to medical cannabis.

Key points

  • The pilot trials are scientific studies on non-medical cannabis use by adults. They are based on Art. 8a BetmG and the BetmPV, limited until 14 May 2031.
  • The FOPH lists eight authorised pilot trials, including in Basel-Stadt, Zurich, Bern, Biel, Lucerne, Lausanne, Vernier and the canton of St. Gallen.
  • Only adults who already use cannabis and live in the canton of the trial can take part. Pregnant and breastfeeding women and people with a contraindication are excluded.
  • Anyone who needs cannabis for medical reasons is in the wrong place in the pilot trials. Since August 2022, medical cannabis has been prescribed by doctors.

The cannabis pilot trials in Switzerland are scientific studies on recreational use. Since 15 May 2021, Art. 8a of the Narcotics Act has allowed adults to buy cannabis legally as part of such trials. The aim is a scientific basis for future regulation.1,2

The trials have nothing to do with medical cannabis. Use for medical reasons on a doctor’s prescription is expressly not the subject of the trials.1 Anyone who wants to use cannabis because of an illness needs a medical assessment and a prescription.

Cannabis with THC-type effects may not be cultivated, imported, manufactured or placed on the market in Switzerland unless it is used for medical purposes (Art. 8 BetmG).2 In 2020, Parliament created an exception with Art. 8a BetmG. After consulting cantons and communes, the FOPH may authorise scientific pilot trials limited in place, time and subject matter. They are intended to show how new rules affect non-medical cannabis use and the health of participants.2

The details are set out in the Ordinance on Pilot Trials under the Narcotics Act (BetmPV). The key points:3,4

  • Place and duration: A trial is limited to one or more communes and lasts at most five years, with a one-off extension of at most two years.
  • Size: At most 5,000 people may take part in each trial.
  • Time limit: The legal basis applies for ten years, from 15 May 2021 to 14 May 2031.
  • Research: A recognised research institute is involved in every trial. The competent ethics committee must approve the study.

Which cannabis pilot trials the FOPH lists

On its overview page, the FOPH lists the following authorised pilot trials. The information on aims summarises the FOPH’s descriptions.5

Pilot trial Location Focus according to the FOPH
CanLeg Canton of St. Gallen demand and use, influence of sales channels, randomised controlled trial
Cann-L City of Lausanne non-profit sale
La Cannabinothèque Vernier (GE) knowledge about use, health and social risks
Cannabis Research Zürich Canton of Zurich social and economic consequences
Grashaus Projects Liestal and Allschwil structured, controlled sale
SCRIPT Bern, Biel, Lucerne non-profit sale in pharmacies with advice
WeedCare Basel-Stadt health effects of sale in pharmacies
ZüriCan City of Zurich advice and lower-risk forms of use

The FOPH does not keep a central directory of organisations with contact details for interested people. It authorises the trials but does not conduct any itself. Those responsible for each project provide information on participation and timing.4 This overview is for information and is not an invitation to take part.

Who may take part and who is excluded

The BetmPV sets out who can take part in a pilot trial. Participants must demonstrably already use cannabis, live in the canton of the trial and consent to the study in writing.3

Excluded are people who:3

  • are minors,
  • lack capacity to judge,
  • are pregnant or breastfeeding,
  • have an illness diagnosed by a doctor for which cannabis use is contraindicated.

There is no entitlement to take part. Participants may only use the products themselves, may not pass them on and may not use them in publicly accessible spaces. Passing them on is sanctioned and, if repeated, leads to exclusion.3 Participants receive an ID card, and the trial must designate a responsible doctor who monitors their state of health.3

Rules for products, sale and advertising

The products in the trials are subject to strict requirements. They are dispensed sealed, and products for oral use are in child-resistant packaging. Among other things, the packaging carries warnings on health risks, addiction and fitness to drive, and a notice that the product must not be passed on to third parties or to anyone under 18.3

The quantity dispensed is based on personal need and is limited per month. Participants pay for the products themselves. The price takes into account the active ingredient content and the local black-market price.3,4 Depending on the trial, sale takes place in pharmacies, non-profit shops, specialist shops or social clubs with trained staff.4,6

Advertising for cannabis products is prohibited in the trials (Art. 12 BetmPV). The FOPH speaks of an absolute advertising ban.1,3

First results from the pilot trials

On behalf of the FOPH, the University of Lausanne and the University of Applied Sciences Northwestern Switzerland evaluated the trials across the board. The final report covers the period from 2022 to July 2025. According to the FOPH, around 10,500 people took part.6

The FOPH summarises: use did not increase despite easier access, there were tendencies towards lower-risk use, and legal supply had no negative effect on the physical and mental health of participants.6 The trials are continuing, and the FOPH is evaluating the data on an ongoing basis. Once all trials are completed, it will prepare a report for the Federal Council.4,6

These results concern people who already used cannabis and recreational use. No conclusions about medical use can be drawn from them.3,6

Difference from medical cannabis

Pilot trials and medical cannabis are based on two different routes in the law:

Pilot trial Medical cannabis
Purpose research on recreational use treatment of an illness
Legal basis Art. 8a BetmG, BetmPV doctor’s prescription, since 1 August 2022 without FOPH authorisation
Access taking part in a study, residence in the canton medical assessment and prescription
Supply point of sale of the trial pharmacy with a narcotics prescription
Costs paid by yourself paid by yourself, health insurer only in individual cases with cost approval

The FOPH clearly answers no to the question of whether you can take part in a pilot trial for medical reasons.4 Since 1 August 2022, doctors may prescribe cannabis medicines without FOPH authorisation. The health insurer only covers the costs in individual cases after cost approval.7 An overview of medical use is given on the Cannabis therapy page.

How it works at evidena

evidena offers exclusively medical assessments and does not arrange participation in pilot trials.4 Whether therapy with cannabis medicines is an option for you is decided by the doctor. If a prescription is issued, it must be filled at the pharmacy within one month. As a rule, the prescribed quantity covers one month, in justified cases at most three months of treatment.8

You can book an appointment at portal.evidena.care/appointments. We answer questions via WhatsApp or at info@evidena.care. How it works is described on the page How it works, the costs on the Costs page.

Conclusion

The pilot trials are time-limited studies on recreational use by adults, not legalisation and not access to medical cannabis. The FOPH lists eight authorised trials.5 If you are considering cannabis for health reasons, the route is a medical assessment. Further legal questions can be found in the Law section.

Frequently asked questions

What are the cannabis pilot trials in Switzerland?

Scientific studies limited in time and place in which adults can legally buy cannabis for recreational purposes. They are intended to provide a basis for future regulation.

Which pilot trials are there?

The FOPH lists CanLeg (canton of St. Gallen), Cann-L (Lausanne), La Cannabinothèque (Vernier), Cannabis Research Zürich, Grashaus Projects (Liestal and Allschwil), SCRIPT (Bern, Biel, Lucerne), WeedCare (Basel-Stadt) and ZüriCan (city of Zurich).

Can I take part in a pilot trial to use cannabis medically?

No. The trials exclusively study non-medical use. For medical use, a doctor's prescription is the route.

Do the pilot trials make cannabis legal in Switzerland?

No. Outside the trials, recreational cannabis remains prohibited. The exception only applies to registered participants within their trial.

Will my employer find out about my participation?

According to the FOPH, participant data may not be passed on to third parties such as authorities or employers. The FOPH only receives anonymised data.

Your situation is individual

Discuss your questions with a doctor.

Book a consultation

Sources

  1. Pilotversuche mit Cannabis, Bundesamt für Gesundheit BAG (accessed 13 November 2026)
  2. Betäubungsmittelgesetz (BetmG), SR 812.121, Art. 8 und 8a, Fedlex (accessed 13 November 2026)
  3. Verordnung über Pilotversuche nach dem Betäubungsmittelgesetz (BetmPV), SR 812.121.5, Art. 5, 6, 11, 12, 14 bis 19, Fedlex (accessed 13 November 2026)
  4. FAQ: Häufige Fragen zu Pilotversuchen mit Cannabis, Bundesamt für Gesundheit BAG (accessed 13 November 2026)
  5. Übersicht über die bewilligten Pilotversuche mit Cannabis, Bundesamt für Gesundheit BAG (accessed 13 November 2026)
  6. Ergebnisse aus den Pilotversuchen mit Cannabis, Bundesamt für Gesundheit BAG (accessed 13 November 2026)
  7. FAQ Cannabisarzneimittel, Bundesamt für Gesundheit BAG, 4. März 2025 (accessed 13 November 2026)
  8. Betäubungsmittelkontrollverordnung (BetmKV), SR 812.121.1, Art. 46 und 47, Stand am 23. Januar 2023, Fedlex (accessed 13 November 2026)

Written by evidena.care editorial team · Published 13 November 2026 · Reviewed 13 November 2026

This article is general information and does not replace medical advice. Whether cannabis therapy is an option for you is decided by a doctor in a personal consultation.